About CJC-1295 Medicine

What this site is

CJC-1295 Medicine is an unrolled handscroll of the peer-reviewed research literature on CJC-1295 — a reading of published studies, laid out as a scroll of what the medical literature actually contains. No clinic stands behind it and no clinician is on staff; it prescribes nothing, gives no medical advice, and makes, sells, or ships no product. It reads the published science and cites every number it reports.

The word 'Medicine' in the domain name is editorial framing — a position the publisher occupies relative to the medical literature, not a claim about the site's services. CJC-1295 Medicine reads medical research; it does not practice medicine.

Developmental history

CJC-1295 was developed by ConjuChem Inc. of Montreal in the early 2000s ^[02][03]. The company's Drug Affinity Complex (DAC) technology — a maleimidopropionyl linker that covalently conjugates a peptide to the free cysteine on human serum albumin — was the structural innovation that made weekly dosing of a GHRH analog plausible ^[12]. The original preclinical paper (Jetté et al., Endocrinology, 2005) identified CJC-1295 as the most potent of three maleimido hGRF(1-29) bioconjugates the company synthesized, and the human Phase 1 paper (Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006) established the 5.8- to 8.1-day plasma half-life in healthy adults ^[01][03].

A Phase 2 trial registered on ClinicalTrials.gov as NCT00267527 studied weekly escalating doses in HIV-associated visceral obesity ^[18]. The trial enrolled approximately 192 participants and was terminated in 2006 following a single participant fatality, reported as myocardial infarction; the attending physician's determination was pre-existing coronary artery disease rather than the study drug ^[07]. ConjuChem wound down its broader DAC peptide program. No late-stage CJC-1295 trial has resumed in the twenty years since.

Human clinical record

At least four Phase 1 and Phase 1/2 trials are documented in the published literature, including the two ascending-dose trials in healthy adults reported in Teichman 2006 ^[01] and the Phase 2 HIV-lipodystrophy trial NCT00267527 ^[18]. Late-stage development never resumed. The peer-reviewed human pharmacology record on CJC-1295 today is essentially the Teichman 2006 paper plus the registry trace of the discontinued Phase 2 program. Most of what circulates about CJC-1295 outside the peer-reviewed literature derives from one Phase 1 paper and unpublished Phase 2 data.

Discontinuation of the clinical program

Public records cite the 2006 Phase 2 fatality as a factor in the suspension of ConjuChem's broader DAC peptide program ^[07]. CJC-1295 was never independently linked to that event in published reporting; the attending physician's determination was underlying coronary artery disease. But the silence that followed — no late-stage trials, no published Phase 2 efficacy data, no continued safety surveillance — is the editorial fact of the program's history. The scroll closes here, with a half-pressed seal.

What this site does not do

This site makes, sells, and ships nothing — not CJC-1295, not any other peptide. It recommends no dose and offers no medical advice. No clinicians, pharmacists, or other healthcare staff work on it, and it provides no treatment, consultation, or prescription. It is a scroll that reads the peer-reviewed literature in plain English and cites every number it reports.

Readers interested in the underlying primary papers will find each linked on the references and citations page. Readers with a question about a specific section of the literature are welcome to reach the editorial desk through the contact page.